These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

216 related items for PubMed ID: 9080435

  • 1. Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat.
    Navarro M, Hernández E, Muñoz RM, del Arco I, Villanúa MA, Carrera MR, Rodríguez de Fonseca F.
    Neuroreport; 1997 Jan 20; 8(2):491-6. PubMed ID: 9080435
    [Abstract] [Full Text] [Related]

  • 2. Reversal of SR 141716A-induced head-twitch and ear-scratch responses in mice by delta 9-THC and other cannabinoids.
    Janoyan JJ, Crim JL, Darmani NA.
    Pharmacol Biochem Behav; 2002 Jan 20; 71(1-2):155-62. PubMed ID: 11812518
    [Abstract] [Full Text] [Related]

  • 3. CB1 cannabinoid receptors mediate anxiolytic effects: convergent genetic and pharmacological evidence with CB1-specific agents.
    Haller J, Varga B, Ledent C, Freund TF.
    Behav Pharmacol; 2004 Jul 20; 15(4):299-304. PubMed ID: 15252281
    [Abstract] [Full Text] [Related]

  • 4. The CB1 cannabinoid receptor antagonist SR 141716A affects A9 dopamine neuronal activity in the rat.
    Gueudet C, Santucci V, Rinaldi-Carmona M, Soubrié P, Le Fur G.
    Neuroreport; 1995 Jul 10; 6(10):1421-5. PubMed ID: 7488739
    [Abstract] [Full Text] [Related]

  • 5. Delta(9)-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB(1) receptor antagonist/inverse agonist SR 141716A.
    Darmani NA.
    Neuropsychopharmacology; 2001 Feb 10; 24(2):198-203. PubMed ID: 11120402
    [Abstract] [Full Text] [Related]

  • 6. SR 141716A acts as an inverse agonist to increase neuronal voltage-dependent Ca2+ currents by reversal of tonic CB1 cannabinoid receptor activity.
    Pan X, Ikeda SR, Lewis DL.
    Mol Pharmacol; 1998 Dec 10; 54(6):1064-72. PubMed ID: 9855635
    [Abstract] [Full Text] [Related]

  • 7. SR 141716A, a CB1 cannabinoid receptor antagonist, potentiates the locomotor stimulant effects of amphetamine and apomorphine.
    Masserano JM, Karoum F, Wyatt RJ.
    Behav Pharmacol; 1999 Jul 10; 10(4):429-32. PubMed ID: 10780811
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The cannabinoid CB1 antagonist N-piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl) -4-methylpyrazole-3-carboxamide (SR-141716A) differentially alters the reinforcing effects of heroin under continuous reinforcement, fixed ratio, and progressive ratio schedules of drug self-administration in rats.
    Solinas M, Panlilio LV, Antoniou K, Pappas LA, Goldberg SR.
    J Pharmacol Exp Ther; 2003 Jul 10; 306(1):93-102. PubMed ID: 12660305
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Cannabinoid precipitated withdrawal by the selective cannabinoid receptor antagonist, SR 141716A.
    Aceto MD, Scates SM, Lowe JA, Martin BR.
    Eur J Pharmacol; 1995 Aug 25; 282(1-3):R1-2. PubMed ID: 7498260
    [Abstract] [Full Text] [Related]

  • 12. Characterization and distribution of binding sites for [3H]-SR 141716A, a selective brain (CB1) cannabinoid receptor antagonist, in rodent brain.
    Rinaldi-Carmona M, Pialot F, Congy C, Redon E, Barth F, Bachy A, Brelière JC, Soubrié P, Le Fur G.
    Life Sci; 1996 Aug 25; 58(15):1239-47. PubMed ID: 8614277
    [Abstract] [Full Text] [Related]

  • 13. The cannabinoid CB1 receptor antagonist SR 141716A induces penile erection by increasing extra-cellular glutamic acid in the paraventricular nucleus of male rats.
    Succu S, Mascia MS, Sanna F, Melis T, Argiolas A, Melis MR.
    Behav Brain Res; 2006 May 15; 169(2):274-81. PubMed ID: 16516985
    [Abstract] [Full Text] [Related]

  • 14. SR 141716A, a cannabinoid receptor antagonist, produces hyperalgesia in untreated mice.
    Richardson JD, Aanonsen L, Hargreaves KM.
    Eur J Pharmacol; 1997 Jan 29; 319(2-3):R3-4. PubMed ID: 9042616
    [Abstract] [Full Text] [Related]

  • 15. SR-141716A-induced stimulation of locomotor activity. A structure-activity relationship study.
    Bass CE, Griffin G, Grier M, Mahadevan A, Razdan RK, Martin BR.
    Pharmacol Biochem Behav; 2002 Dec 29; 74(1):31-40. PubMed ID: 12376150
    [Abstract] [Full Text] [Related]

  • 16. 'One-trial sensitization' to the anxiolytic-like effects of cannabinoid receptor antagonist SR141716A in the mouse elevated plus-maze.
    Rodgers RJ, Haller J, Halasz J, Mikics E.
    Eur J Neurosci; 2003 Mar 29; 17(6):1279-86. PubMed ID: 12670316
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Arousal-enhancing properties of the CB1 cannabinoid receptor antagonist SR 141716A in rats as assessed by electroencephalographic spectral and sleep-waking cycle analysis.
    Santucci V, Storme JJ, Soubrié P, Le Fur G.
    Life Sci; 1996 Mar 29; 58(6):PL103-10. PubMed ID: 8569415
    [Abstract] [Full Text] [Related]

  • 19. Effects of cannabinoid receptor ligands on psychosis-relevant behavior models in the rat.
    Martin RS, Secchi RL, Sung E, Lemaire M, Bonhaus DW, Hedley LR, Lowe DA.
    Psychopharmacology (Berl); 2003 Jan 29; 165(2):128-35. PubMed ID: 12404071
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.